Allergan has announced it will acquire Boston-based Motus Therapeutics for $200 million.
Motus Therapeutics (formerly Rhythm Health) is a subsidiary of Boston-based Rhythm Holding Company.
Allergan had an option to acquire Motus based on a deal that Rhythm struck with Actavis, after Actavis merged with Allergan in 2015.
Allergan exercised its option after Motus released postive results from a Phase 2b study into its experimental drug, relamorelin. The drug aims to treat a type of gastroparesis related to diabetes, in which the stomach doesn’t empty into the intestine quickly enough, leading to abdominal pain, bloating, and vomiting.
Read the Xconomy coverage